PTAB Shuts Down Another Bass AIA Review Of Horizon Drug
The Patent Trial and Appeal Board on Thursday said it will not conduct an inter partes review of a patent on Horizon Pharma PLC's arthritis medication Vimovo requested by hedge fund...To view the full article, register now.
Already a subscriber? Click here to view full article